

Cell-derived liposomes for drug delivery (Technion)

code: DDL-1161

A major challenge facing cancer therapy is achieving specific cytotoxic effect towards cancer cells while sparing the healthy ones. This invention describes the development of an innovative targeted system for cancer therapy based on mesenchymal stem cell (MSC) derived liposomes. The engineered liposome may contain variety of anti-cancer or cytotoxin compounds which will be released directly into the cancer cells.

Contact for more information:

Santiago Ini , +972-4-8294856

T - Technion Technology Transfer
Technion City, Senate Bldg., Haifa 32000, Israel
Tel. 972-4-829-4851; 972-8325-375
Fax. 972-4-832-0845